RT Journal Article
SR Electronic
T1 Single-Cell Analysis Reveals Macrophage-Driven T Cell Dysfunction in Severe COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.23.20100024
DO 10.1101/2020.05.23.20100024
A1 Xiaoqing Liu
A1 Airu Zhu
A1 Jiangping He
A1 Zhao Chen
A1 Longqi Liu
A1 Yuanda Xu
A1 Feng Ye
A1 Huijian Feng
A1 Ling Luo
A1 Baomei Cai
A1 Yuanbang Mai
A1 Lihui Lin
A1 Zhenkun Zhuang
A1 Sibei Chen
A1 Junjie Shi
A1 Liyan Wen
A1 Yuanjie Wei
A1 Jianfen Zhuo
A1 Yingying Zhao
A1 Fang Li
A1 Xiaoyu Wei
A1 Dingbin Chen
A1 Xinmei Zhang
A1 Na Zhong
A1 Yaling Huang
A1 He Liu
A1 Jinyong Wang
A1 Xun Xu
A1 Jie Wang
A1 Ruchong Chen
A1 Xinwen Chen
A1 Nanshan Zhong
A1 Jingxian Zhao
A1 Yi-min Li
A1 Jincun Zhao
A1 Jiekai Chen
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.23.20100024.abstract
AB The vastly spreading COVID-19 pneumonia is caused by SARS-CoV-2. Lymphopenia and cytokine levels are tightly associated with disease severity. However, virus-induced immune dysregulation at cellular and molecular levels remains largely undefined. Here, the leukocytes in the pleural effusion, sputum, and peripheral blood biopsies from severe and mild patients were analyzed at single-cell resolution. Drastic T cell hyperactivation accompanying elevated T cell exhaustion was observed, predominantly in pleural effusion. The mechanistic investigation identified a group of CD14+ monocytes and macrophages highly expressing CD163 and MRC1 in the biopsies from severe patients, suggesting M2 macrophage polarization. These M2-like cells exhibited up-regulated IL10, CCL18, APOE, CSF1 (M-CSF), and CCL2 signaling pathways. Further, SARS-CoV-2-specific T cells were observed in pleural effusion earlier than in peripheral blood. Together, our results suggest that severe SARS-CoV-2 infection causes immune dysregulation by inducing M2 polarization and subsequent T cell exhaustion. This study improves our understanding of COVID-19 pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by grants from the National Key Research and Development Program of China (2019YFA0110200, 2018YFC1200100, 2018ZX10301403), the special project for COVID-19 of Guangzhou Regenerative Medicine and Health Guangdong Laboratory(2020GZR110106006), the emergency grants for prevention and control of SARS-CoV-2 of Ministry of Science and Technology (2020YFC0841400) and Guangdong province (2020B111108001, 2018B020207013). We thank the patient who took part in this study. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No related informationsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request